AG˹ٷ

STOCK TITAN

[Form 4] IDEAYA Biosciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Iron Mountain Inc. (NYSE: IRM) � Form 144 filing: CEO William L. Meaney has filed a notice of proposed sale for 69,125 common shares through Fidelity Brokerage, with an aggregate market value of roughly $7.05 million. The shares represent only 0.023% of the company’s 295.0 million shares outstanding. The anticipated sale date is 01 July 2025.

The filing shows the shares were acquired via an option granted on 18 Feb 2016 and exercised on 01 July 2025, paid in cash. Meaney has already sold 207,375 shares over the last three months (01 Apr, 02 May, 02 Jun 2025) generating � $19.5 million in gross proceeds. The current notice is therefore a continuation of an ongoing liquidation program, likely under a Rule 10b5-1 trading plan (the form requests plan-adoption date but leaves that field blank).

Because Form 144 is only a notice of intent, the sale may or may not be completed. While insider selling by the CEO can draw investor attention, the percentage of total shares is immaterial and does not directly affect the company’s capital structure or operations. Investors should watch subsequent Form 4 filings to confirm execution and to gauge any larger trend in executive share disposition.

Iron Mountain Inc. (NYSE: IRM) � Comunicazione Form 144: Il CEO William L. Meaney ha presentato un avviso di vendita proposta per 69.125 azioni ordinarie tramite Fidelity Brokerage, con un valore di mercato complessivo di circa 7,05 milioni di dollari. Le azioni rappresentano solo lo 0,023% delle 295,0 milioni di azioni in circolazione della società. La data prevista per la vendita è il 1 luglio 2025.

La comunicazione indica che le azioni sono state acquisite tramite un opzione concessa il 18 febbraio 2016 ed esercitata il 1 luglio 2025, con pagamento in contanti. Meaney ha già venduto 207.375 azioni negli ultimi tre mesi (1 aprile, 2 maggio, 2 giugno 2025), generando circa 19,5 milioni di dollari di ricavi lordi. L’avviso attuale rappresenta quindi la continuazione di un programma di liquidazione in corso, probabilmente nell’ambito di un piano di trading Rule 10b5-1 (il modulo richiede la data di adozione del piano ma questo campo è lasciato vuoto).

Poiché il Form 144 è solo un avviso di intenzione, la vendita potrebbe non essere completata. Sebbene la vendita da parte del CEO possa attirare l’attenzione degli investitori, la percentuale del totale delle azioni è irrilevante e non influisce direttamente sulla struttura del capitale o sulle operazioni della società. Gli investitori dovrebbero monitorare i successivi moduli Form 4 per confermare l’esecuzione e valutare eventuali tendenze più ampie nella cessione di azioni da parte dei dirigenti.

Iron Mountain Inc. (NYSE: IRM) � Presentación del Formulario 144: El CEO William L. Meaney ha presentado un aviso de venta propuesta de 69,125 acciones comunes a través de Fidelity Brokerage, con un valor de mercado agregado de aproximadamente 7,05 millones de dólares. Las acciones representan solo el 0,023% de los 295,0 millones de acciones en circulación de la compañía. La fecha prevista para la venta es el 1 de julio de 2025.

La presentación muestra que las acciones fueron adquiridas mediante una opción otorgada el 18 de febrero de 2016 y ejercida el 1 de julio de 2025, pagada en efectivo. Meaney ya ha vendido 207,375 acciones en los últimos tres meses (1 de abril, 2 de mayo, 2 de junio de 2025), generando aproximadamente 19,5 millones de dólares en ingresos brutos. El aviso actual es, por lo tanto, una continuación de un programa de liquidación en curso, probablemente bajo un plan de negociación Rule 10b5-1 (el formulario solicita la fecha de adopción del plan pero ese campo está en blanco).

Dado que el Formulario 144 es solo un aviso de intención, la venta puede o no completarse. Aunque la venta por parte del CEO puede atraer la atención de los inversores, el porcentaje del total de acciones es insignificante y no afecta directamente la estructura de capital o las operaciones de la empresa. Los inversores deben observar las presentaciones posteriores del Formulario 4 para confirmar la ejecución y evaluar cualquier tendencia mayor en la disposición de acciones por parte de los ejecutivos.

Iron Mountain Inc. (NYSE: IRM) � Form 144 제출: CEO William L. Meaney가 Fidelity Brokerage� 통해 69,125 보통� 매도 예정 통지� 제출했으�, � 시장 가� � 705� 달러� 해당합니�. 해당 주식은 회사� � 발행 주식 2� 9,500� � � 0.023%� 불과합니�. 예상 매도일은 2025� 7� 1�입니�.

제출서류� 따르� � 주식은 2016� 2� 18� 부여된 옵션� 통해 취득하였으며, 2025� 7� 1� 현금으로 행사되었습니�. Meaney� 지� 3개월� (2025� 4� 1�, 5� 2�, 6� 2�) 이미 207,375�� 매도하여 � 1,950� 달러� � 수익� 올렸습니�. 이번 통지� 지� 중인 청산 프로그램� 연장선으� 보이�, 아마� Rule 10b5-1 거래 계획� 따른 것일 가능성� 큽니�(양식� 계획 채택일을 기입하는 칸이 있으� 비워� 있습니다).

Form 144� 단지 의도 통지이므� 매도가 반드� 이루어지� 것은 아닙니다. CEO� 내부� 매도� 투자자의 관심을 � � 있으�, 전체 주식 대� 비율은 미미

Iron Mountain Inc. (NYSE : IRM) � Dépôt du formulaire 144 : Le PDG William L. Meaney a déposé un avis de vente proposée de 69 125 actions ordinaires via Fidelity Brokerage, pour une valeur marchande totale d'environ 7,05 millions de dollars. Ces actions représentent seulement 0,023 % des 295,0 millions d'actions en circulation de la société. La date prévue de la vente est le 1er juillet 2025.

Le dépôt indique que les actions ont été acquises via une option accordée le 18 février 2016 et exercée le 1er juillet 2025, payée en espèces. Meaney a déjà vendu 207 375 actions au cours des trois derniers mois (1er avril, 2 mai, 2 juin 2025), générant environ 19,5 millions de dollars de produit brut. L'avis actuel constitue donc la poursuite d'un programme de liquidation en cours, probablement dans le cadre d'un plan de négociation Rule 10b5-1 (le formulaire demande la date d'adoption du plan, mais ce champ est laissé vide).

Comme le formulaire 144 n'est qu'un avis d'intention, la vente peut ou non être réalisée. Bien que la vente par le PDG puisse attirer l'attention des investisseurs, le pourcentage du total des actions est négligeable et n'affecte pas directement la structure du capital ou les opérations de la société. Les investisseurs devraient surveiller les dépôts ultérieurs du formulaire 4 pour confirmer l'exécution et évaluer toute tendance plus large dans la cession d'actions par les dirigeants.

Iron Mountain Inc. (NYSE: IRM) � Form 144 Einreichung: CEO William L. Meaney hat eine Mitteilung über den geplanten Verkauf von 69.125 Stammaktien über Fidelity Brokerage eingereicht, mit einem gesamtmarktwert von etwa 7,05 Millionen US-Dollar. Die Aktien entsprechen nur 0,023 % der 295,0 Millionen ausstehenden Aktien des Unternehmens. Das erwartete Verkaufsdatum ist der 1. Juli 2025.

Die Einreichung zeigt, dass die Aktien durch eine Option erworben wurden, die am 18. Februar 2016 gewährt und am 1. Juli 2025 ausgeübt wurde, bezahlt in bar. Meaney hat in den letzten drei Monaten (1. April, 2. Mai, 2. Juni 2025) bereits 207.375 Aktien verkauft und dabei ca. 19,5 Millionen US-Dollar Bruttoerlös erzielt. Die aktuelle Mitteilung stellt somit eine Fortsetzung eines laufenden Liquidationsprogramms dar, wahrscheinlich im Rahmen eines Rule 10b5-1 Handelsplans (das Formular verlangt das Datum der Planannahme, dieses Feld ist jedoch leer).

Da das Formular 144 nur eine ٲäܲԲ ist, kann der Verkauf durchgeführt werden oder auch nicht. Obwohl der Insider-Verkauf durch den CEO die Aufmerksamkeit der Investoren auf sich ziehen kann, ist der Prozentsatz der Gesamtaktien unerheblich und wirkt sich nicht direkt auf die Kapitalstruktur oder den Geschäftsbetrieb des Unternehmens aus. Investoren sollten nachfolgende Form 4 Einreichungen beobachten, um die Ausführung zu bestätigen und mögliche größere Trends bei der Veräußerung von Aktien durch Führungskräfte zu erkennen.

Positive
  • None.
Negative
  • Continued insider selling by the CEO—total of 276,500 shares over four months—could raise perception concerns despite representing only ~0.09% of shares outstanding.

Insights

TL;DR: Minor CEO share sale (0.02% float); signals limited, monitor for cumulative insider trends.

The planned 69,125-share sale equates to roughly one trading day’s volume and will have negligible market-impact on IRM’s float. Because the shares stem from long-dated option exercises, this looks like routine diversification. The three prior equal-sized monthly sales reinforce that narrative. That said, continued insider selling by the CEO can create a negative optics issue if compounded by additional executives. I rate the filing as neutral; valuation and fundamentals remain unchanged.

TL;DR: Governance risk low; Rule 144 notice respects disclosure norms.

Meaney’s repeated, evenly spaced sales suggest a pre-arranged Rule 10b5-1 plan, mitigating concerns of trading on undisclosed information. The small stake reduction (<0.1% of his total holdings assuming historical data) does not materially alter alignment between management and shareholders. No adverse governance red flags detected, but investors should verify upcoming Form 4s for compliance with the company’s insider-trading policy.

Iron Mountain Inc. (NYSE: IRM) � Comunicazione Form 144: Il CEO William L. Meaney ha presentato un avviso di vendita proposta per 69.125 azioni ordinarie tramite Fidelity Brokerage, con un valore di mercato complessivo di circa 7,05 milioni di dollari. Le azioni rappresentano solo lo 0,023% delle 295,0 milioni di azioni in circolazione della società. La data prevista per la vendita è il 1 luglio 2025.

La comunicazione indica che le azioni sono state acquisite tramite un opzione concessa il 18 febbraio 2016 ed esercitata il 1 luglio 2025, con pagamento in contanti. Meaney ha già venduto 207.375 azioni negli ultimi tre mesi (1 aprile, 2 maggio, 2 giugno 2025), generando circa 19,5 milioni di dollari di ricavi lordi. L’avviso attuale rappresenta quindi la continuazione di un programma di liquidazione in corso, probabilmente nell’ambito di un piano di trading Rule 10b5-1 (il modulo richiede la data di adozione del piano ma questo campo è lasciato vuoto).

Poiché il Form 144 è solo un avviso di intenzione, la vendita potrebbe non essere completata. Sebbene la vendita da parte del CEO possa attirare l’attenzione degli investitori, la percentuale del totale delle azioni è irrilevante e non influisce direttamente sulla struttura del capitale o sulle operazioni della società. Gli investitori dovrebbero monitorare i successivi moduli Form 4 per confermare l’esecuzione e valutare eventuali tendenze più ampie nella cessione di azioni da parte dei dirigenti.

Iron Mountain Inc. (NYSE: IRM) � Presentación del Formulario 144: El CEO William L. Meaney ha presentado un aviso de venta propuesta de 69,125 acciones comunes a través de Fidelity Brokerage, con un valor de mercado agregado de aproximadamente 7,05 millones de dólares. Las acciones representan solo el 0,023% de los 295,0 millones de acciones en circulación de la compañía. La fecha prevista para la venta es el 1 de julio de 2025.

La presentación muestra que las acciones fueron adquiridas mediante una opción otorgada el 18 de febrero de 2016 y ejercida el 1 de julio de 2025, pagada en efectivo. Meaney ya ha vendido 207,375 acciones en los últimos tres meses (1 de abril, 2 de mayo, 2 de junio de 2025), generando aproximadamente 19,5 millones de dólares en ingresos brutos. El aviso actual es, por lo tanto, una continuación de un programa de liquidación en curso, probablemente bajo un plan de negociación Rule 10b5-1 (el formulario solicita la fecha de adopción del plan pero ese campo está en blanco).

Dado que el Formulario 144 es solo un aviso de intención, la venta puede o no completarse. Aunque la venta por parte del CEO puede atraer la atención de los inversores, el porcentaje del total de acciones es insignificante y no afecta directamente la estructura de capital o las operaciones de la empresa. Los inversores deben observar las presentaciones posteriores del Formulario 4 para confirmar la ejecución y evaluar cualquier tendencia mayor en la disposición de acciones por parte de los ejecutivos.

Iron Mountain Inc. (NYSE: IRM) � Form 144 제출: CEO William L. Meaney가 Fidelity Brokerage� 통해 69,125 보통� 매도 예정 통지� 제출했으�, � 시장 가� � 705� 달러� 해당합니�. 해당 주식은 회사� � 발행 주식 2� 9,500� � � 0.023%� 불과합니�. 예상 매도일은 2025� 7� 1�입니�.

제출서류� 따르� � 주식은 2016� 2� 18� 부여된 옵션� 통해 취득하였으며, 2025� 7� 1� 현금으로 행사되었습니�. Meaney� 지� 3개월� (2025� 4� 1�, 5� 2�, 6� 2�) 이미 207,375�� 매도하여 � 1,950� 달러� � 수익� 올렸습니�. 이번 통지� 지� 중인 청산 프로그램� 연장선으� 보이�, 아마� Rule 10b5-1 거래 계획� 따른 것일 가능성� 큽니�(양식� 계획 채택일을 기입하는 칸이 있으� 비워� 있습니다).

Form 144� 단지 의도 통지이므� 매도가 반드� 이루어지� 것은 아닙니다. CEO� 내부� 매도� 투자자의 관심을 � � 있으�, 전체 주식 대� 비율은 미미

Iron Mountain Inc. (NYSE : IRM) � Dépôt du formulaire 144 : Le PDG William L. Meaney a déposé un avis de vente proposée de 69 125 actions ordinaires via Fidelity Brokerage, pour une valeur marchande totale d'environ 7,05 millions de dollars. Ces actions représentent seulement 0,023 % des 295,0 millions d'actions en circulation de la société. La date prévue de la vente est le 1er juillet 2025.

Le dépôt indique que les actions ont été acquises via une option accordée le 18 février 2016 et exercée le 1er juillet 2025, payée en espèces. Meaney a déjà vendu 207 375 actions au cours des trois derniers mois (1er avril, 2 mai, 2 juin 2025), générant environ 19,5 millions de dollars de produit brut. L'avis actuel constitue donc la poursuite d'un programme de liquidation en cours, probablement dans le cadre d'un plan de négociation Rule 10b5-1 (le formulaire demande la date d'adoption du plan, mais ce champ est laissé vide).

Comme le formulaire 144 n'est qu'un avis d'intention, la vente peut ou non être réalisée. Bien que la vente par le PDG puisse attirer l'attention des investisseurs, le pourcentage du total des actions est négligeable et n'affecte pas directement la structure du capital ou les opérations de la société. Les investisseurs devraient surveiller les dépôts ultérieurs du formulaire 4 pour confirmer l'exécution et évaluer toute tendance plus large dans la cession d'actions par les dirigeants.

Iron Mountain Inc. (NYSE: IRM) � Form 144 Einreichung: CEO William L. Meaney hat eine Mitteilung über den geplanten Verkauf von 69.125 Stammaktien über Fidelity Brokerage eingereicht, mit einem gesamtmarktwert von etwa 7,05 Millionen US-Dollar. Die Aktien entsprechen nur 0,023 % der 295,0 Millionen ausstehenden Aktien des Unternehmens. Das erwartete Verkaufsdatum ist der 1. Juli 2025.

Die Einreichung zeigt, dass die Aktien durch eine Option erworben wurden, die am 18. Februar 2016 gewährt und am 1. Juli 2025 ausgeübt wurde, bezahlt in bar. Meaney hat in den letzten drei Monaten (1. April, 2. Mai, 2. Juni 2025) bereits 207.375 Aktien verkauft und dabei ca. 19,5 Millionen US-Dollar Bruttoerlös erzielt. Die aktuelle Mitteilung stellt somit eine Fortsetzung eines laufenden Liquidationsprogramms dar, wahrscheinlich im Rahmen eines Rule 10b5-1 Handelsplans (das Formular verlangt das Datum der Planannahme, dieses Feld ist jedoch leer).

Da das Formular 144 nur eine ٲäܲԲ ist, kann der Verkauf durchgeführt werden oder auch nicht. Obwohl der Insider-Verkauf durch den CEO die Aufmerksamkeit der Investoren auf sich ziehen kann, ist der Prozentsatz der Gesamtaktien unerheblich und wirkt sich nicht direkt auf die Kapitalstruktur oder den Geschäftsbetrieb des Unternehmens aus. Investoren sollten nachfolgende Form 4 Einreichungen beobachten, um die Ausführung zu bestätigen und mögliche größere Trends bei der Veräußerung von Aktien durch Führungskräfte zu erkennen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MACKEY CATHERINE J

(Last) (First) (Middle)
C/O IDEAYA BIOSCIENCES, INC.
5000 SHORELINE COURT, SUITE 300

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $21.78 06/24/2025 A 20,000 (1) 06/24/2035 Common Stock 20,000 $0 20,000 D
Explanation of Responses:
1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.
/s/ Andres Ruiz Briseno, as Attorney-in-Fact for Catherine J. Mackey 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Iron Mountain (IRM) shares does the CEO plan to sell under this Form 144?

The filing covers 69,125 common shares with an estimated market value of $7.05 million.

What percentage of Iron Mountain’s outstanding shares does 69,125 shares represent?

Approximately 0.023% of the total 295,043,896 shares outstanding.

Has the CEO sold IRM shares recently?

Yes. Over the past three months, he sold 207,375 shares for about $19.5 million in gross proceeds.

Does a Form 144 guarantee the sale will occur?

No. Form 144 is a notice of intent; execution is later confirmed via Form 4 after the trade.

What is the expected sale date for the shares?

The approximate sale date listed is 01 July 2025.
Ideaya Biosciences

NASDAQ:IDYA

IDYA Rankings

IDYA Latest News

IDYA Latest SEC Filings

IDYA Stock Data

2.11B
86.79M
0.91%
116.53%
13.4%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO